AI English summary of an SEC filing — figures as filed
AbbVie ABBVFor the 3 months ended March 31, 2025, AbbVie reported worldwide net revenues of $13.3 billion, operating earnings of $3.7 billion and diluted earnings per share of $0.72. Net revenues increased 8% on a reported basis and 10% on a constant currency basis.
Key points
AI summaryFor the 3 months ended March 31, 2025, AbbVie reported worldwide net revenues of $13.3 billion, operating earnings of $3.7 billion and diluted earnings per share of $0.72. Net revenues increased 8% on a reported basis and 10% on a constant currency basis.
On a constant currency basis, the company said Skyrizi net revenues increased 72% and Rinvoq increased 60%, while Humira decreased 50%. It cited the continued impact of direct biosimilar competition following the loss of exclusivity as a factor in the Humira decline.
The company said other expense, net for Q1 2025 included charges related to changes in fair value of contingent consideration liabilities of $1.5 billion, compared with $660 million in the prior-year quarter. It added that the change in fair value reflected higher estimated Skyrizi sales, the passage of time and lower discount rates.
AbbVie said operating cash flows for Q1 2025 were $1.6 billion, it paid cash dividends of $2.9 billion, issued unsecured senior notes totaling $4.0 billion in aggregate principal and repaid 3.80% senior notes of $3.0 billion in aggregate principal.
Key figures
Quarter ended March 31, 2025
- Revenue
- $13.3B
- Operating income
- $3.7B
- Net income
- $1.3B
- EPS
- $0.72
- Operating cash flow
- $1.6B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q1 2025 Consolidated Results Summary
For the 3 months ended March 31, 2025, AbbVie reported worldwide net revenues of $13.3 billion, operating earnings of $3.7 billion and diluted earnings per share of $0.72. Net revenues increased 8% on a reported basis and 10% on a constant currency basis.
Source · Based on the MD&A text of the filing
Skyrizi, Rinvoq and Humira Revenue Changes by Product
On a constant currency basis, the company said Skyrizi net revenues increased 72% and Rinvoq increased 60%, while Humira decreased 50%. It cited the continued impact of direct biosimilar competition following the loss of exclusivity as a factor in the Humira decline.
Source · Based on the MD&A text of the filing
Changes in Fair Value of Contingent Consideration Liabilities $1.5 billion
The company said other expense, net for Q1 2025 included charges related to changes in fair value of contingent consideration liabilities of $1.5 billion, compared with $660 million in the prior-year quarter. It added that the change in fair value reflected higher estimated Skyrizi sales, the passage of time and lower discount rates.
Source · Based on the MD&A text of the filing
Q1 2025 Operating Cash Flows and Dividend and Debt Activities
AbbVie said operating cash flows for Q1 2025 were $1.6 billion, it paid cash dividends of $2.9 billion, issued unsecured senior notes totaling $4.0 billion in aggregate principal and repaid 3.80% senior notes of $3.0 billion in aggregate principal.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…